Search

Displaying results 5241 - 5250 of 7540 in total
  1. Drug

    4-(Isopropylamino)diphenylamine

    go.drugbank.com/drugs/DB14195
    Approved

    Sensitivity to this compound may be identified with a clinical patch test.

    Synonyms: N-Fenyl-N'-isopropyl-p-fenylendiamin, 1,4-Benzenediamine, N-(1-methylethyl)-N'-phenyl-
  2. Drug

    Tranilast

    go.drugbank.com/drugs/DB07615
    Investigational

    Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma.

    Categories: Analgesics, Non-NarcoticSynonyms: N-(3,4-Dimethoxycinnamoyl)anthranilic acid
  3. Drug

    Synephrine

    go.drugbank.com/drugs/DB09203
    Investigational

    It is present in approved drug products as neo-synephrine, its m-substituted analog. p-synephrine and m-synephrine are known for their longer acting adrenergic effects compared to norepinephrine. … Synephrine, also referred to as, p-synephrine, is naturally occurring alkaloid.

  4. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    compared to interferon and ribavirin alone. … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.

  5. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

  6. Drug

    PIKA rabies vaccine

    go.drugbank.com/drugs/DB17963
    Investigational

    PIKA rabies vaccine is a novel vaccine developed by YS Biopharma.

  7. Drug

    2G7

    go.drugbank.com/drugs/DB18589
    Experimental

    2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.

  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  9. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  10. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B